DOT1L and breast cancer: A recent study showed that inhibition of DOT1L silences ERα gene and blocks the proliferation of antiestrogen-resistant BC cells, indicating that DOT1L is an attractive epigenetic target for treating endocrine therapy-resistant ER+ BC (51).